Fingolimod

SKU: orb1299367

Description

Fingolimod

Research Area

Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 162359-55-9
• MW: 307.47
• Purity: 99.76%
• Formula: C₁₉H₃₃NO₂
• SMILES: CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1
• Target: PAK,LPL Receptor,S1P Receptor
• Solubility: DMSO:1 mg/mL (3.25 mM);Ethanol:7.69 mg/mL (25.01 mM);Methanol:30 mg/mL (97.57 mM)

Bioactivity

• Target IC50:
  S1P1:0.033 nM
• In Vitro:
  Fingolimod has been reported to reduce LPA synthesis via Inhibition o the lysophospholipase autotaxin.?Fingolimod treatment correlates with a significant elevation of axonal cAMP, a crucial factor for axonal outgrowth. Additionally, Fingolimod significantly reduces LPA levels in the injured nerve.?PF-8380 treatment correlates with improved myelin thicknes
• Cell Research:
  Sciatic nerve crush was performed in wildtype C57BL/6, in immunodeficient Rag1 (-/-) and Foxn1 (-/-) mice. Analyses were based on walking track analysis and electrophysiology, histology, and cAMP formation.?Quantification of different LPA species was performed by liquid chromatography coupled to andem mass spectrometry. furthermore , functional consequences of autotaxin Inhibition b the specific inhibitor PF-8380 an the impact of fingolimod on early cytokine release in the injured sciatic nerve were investigate.

Storage & Handling

• Storage: keep away from direct sunlight,store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

p21 activated kinases, S1P Receptor, S1P, S1PReceptor, FTY 720, FTY720, FTY-720, FTY-720A, Fingolimod, Inhibitor, LPLReceptor, LPL Receptor, LPL, inhibit, PAK, Lysophospholipid Receptor

Compound Identifiers

PubChem CID

107970